Cellebrite DI Ltd. (NASDAQ:CLBT) Shares Sold by Y.D. More Investments Ltd

Key Points

• Y.D. More Investments Ltd reduced its holdings in Cellebrite DI Ltd. by 17.0%, following the sale of 51,175 shares, and now owns about $4.87 million worth of the company's stock.
• Several institutional investors, including FMR LLC and Axon Enterprise Inc., have significantly increased their positions in Cellebrite DI, indicating strong interest and activity in the stock.
• Cellebrite DI has received varying ratings from analysts, with a consensus rating of "Moderate Buy" and an average price target of $22.43, highlighting differing perspectives on its future performance.

Y.D. More Investments Ltd reduced its holdings in shares of Cellebrite DI Ltd. (NASDAQ:CLBT - Free Report) by 17.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 250,559 shares of the company's stock after selling 51,175 shares during the period. Y.D. More Investments Ltd owned approximately 0.10% of Cellebrite DI worth $4,868,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds also recently added to or reduced their stakes in CLBT. Assetmark Inc. acquired a new position in shares of Cellebrite DI in the 1st quarter valued at $33,000. Catalyst Capital Advisors LLC purchased a new stake in Cellebrite DI during the 1st quarter valued at about $51,000. Gen Wealth Partners Inc acquired a new position in shares of Cellebrite DI in the fourth quarter valued at about $85,000. NewEdge Advisors LLC increased its holdings in shares of Cellebrite DI by 600.7% in the fourth quarter. NewEdge Advisors LLC now owns 3,910 shares of the company's stock valued at $86,000 after purchasing an additional 3,352 shares during the period. Finally, Sigma Planning Corp purchased a new position in shares of Cellebrite DI in the first quarter worth about $233,000. 45.88% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

CLBT has been the topic of a number of recent research reports. Needham & Company LLC reiterated a "buy" rating and issued a $24.00 target price on shares of Cellebrite DI in a research report on Friday, June 6th. JPMorgan Chase & Co. decreased their price objective on shares of Cellebrite DI from $29.00 to $25.00 and set an "overweight" rating for the company in a research note on Monday, May 12th. Finally, Wall Street Zen downgraded shares of Cellebrite DI from a "buy" rating to a "hold" rating in a report on Saturday, August 2nd. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $22.43.

Cellebrite DI Price Performance

CLBT stock traded down $0.25 during trading on Friday, hitting $13.57. 988,354 shares of the company traded hands, compared to its average volume of 1,502,080. Cellebrite DI Ltd. has a 1 year low of $13.19 and a 1 year high of $26.30. The company has a market cap of $3.25 billion, a PE ratio of -14.14, a P/E/G ratio of 2.79 and a beta of 1.27. The stock's 50-day simple moving average is $15.19 and its 200 day simple moving average is $18.14.

Cellebrite DI (NASDAQ:CLBT - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported $0.10 EPS for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Cellebrite DI had a negative net margin of 46.34% and a positive return on equity of 35.36%. The business had revenue of $107.55 million for the quarter, compared to analysts' expectations of $109.36 million. During the same quarter last year, the company earned $0.08 EPS. The business's revenue was up 20.0% on a year-over-year basis. Research analysts expect that Cellebrite DI Ltd. will post 0.3 earnings per share for the current year.

About Cellebrite DI

Cellebrite DI Ltd. develops solutions for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific. The company's DI suite of solutions allows users to collect, review, analyze, and manage digital data across the investigative lifecycle with respect to legally sanctioned investigations used in various cases, including child exploitation, homicide, anti-terror, border control, sexual crimes, human trafficking, corporate security, cryptocurrency, and intellectual property theft.